Alira Health Announces its Role as Strategic Advisor to Naxicap

News
Published on:
July 21, 2021
Written by:
jean-louis simon

Alira Health is proud to announce its role as strategic advisor to Naxicap in the equity investment in Ceres Pharma Bv.

The Alira Health strategic, commercial, and regulatory due diligence teams brought their expertise and market insights to analyze the diversified product portfolio of Ceres and the various geographies it is operating in.

 

“We are pleased that Naxicap was able to become the new significant shareholder of Ceres and that Alira Health was part of the effort. The opportunities for Ceres going forward are tremendous and the growth both in Benelux and in Central Europe will certainly be significant,” said Jean-Louis Simon, Senior Partner, Alira Health.

 

Read the full press release here.

Related news

Publications January 20, 2023
Insights on Market Access
To get her perspective on market access and what to expect in 2023, we spoke with Nerea Blanqué, Senior Vice President of Market Access and Pricing at Alira Health.
Market Access Medical Devices Pharma
Publications January 18, 2023
The State of Biopharma Funding
We spoke with Joris Pezzini, Executive Vice President of Biopharma, Alira Health, during the J.P. Morgan Healthcare Conference in San Francisco, which brings together investors and(...)
Biopharma Biotech Funding Pharma
Publications December 21, 2022
2022 Recap: Your Favorite Alira Health Publications
In 2022, the Alira Health team of scientists, strategists, economists, clinicians, and biostatisticians shared actionable insights, industry thought leadership, and leading-edge guidance(...)
Clinical Digital Health Market Access MedTech Pharma Regulatory
Publications November 8, 2022
Debate sobre los IPT en oncología: buscando puntos de mejora en la evaluación y acceso de los fármacos oncológicos en España
For our Spanish community members, we are glad to share the Debate on IPT in oncology: Looking for points of improvement in the evaluation and access of oncological drugs in Spain.
Oncology Pharma Spain
News October 4, 2022
Alira Health enhances its market access services through a strategic partnership with Centivis
Alira Health, a global healthcare advisory and technology company, announced a strategic partnership with Centivis AG, a boutique market access consulting agency, specializing in digital(...)
Digital Health Market Access MedTech Pharma Regulatory
News September 6, 2022
Alira Health Expands North American Capabilities with the Acquisition of Artisan Healthcare Consulting
The acquisition of Artisan strengthens and extends Alira Health’s Market Access and Management Consulting advisory practices in North America and globally.
Biotech Market Access Pharma Therapeutics
Publications August 25, 2022
Why—and When—to Use a CDMO
Pharmaceutical development companies of all sizes frequently outsource their Active Pharmaceutical Ingredient (API) manufacturing to CDMOs for various reasons. In this article, we explore(...)
CDMO Pharma Research and Development
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.